Thank you for joining us.
The program will commence momentarily.

RTP
RESEARCH
TO PRACTICE

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia

A Meet The Professor Series

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Commercial Support

These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.

RTP
RESEARCH
TO PRACTICE

Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

RTP
RESEARCH
TO PRACTICE

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Rogers — Disclosures

Consulting Agreements	AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company
Contracted Research	AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc
Travel	AstraZeneca Pharmaceuticals LP

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program commences and throughout the program.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

RTP RESEARCH TO PRACTICE

Upcoming Live Webinars

Friday, September 11, 2020
12:00 PM – 1:00 PM ET

Clinical Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

Faculty
Robert L Coleman, MD

Moderator
Neil Love, MD

Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 days.

RTP
RESEARCH
TO PRACTICE

ONCOLOGY TODAY

WITH DR NEIL LOVE

Listen on Apple Podcasts

Spotify

Listen on Google Podcasts



Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia

A Meet The Professor Series

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Meet The Professor Program Participating Faculty

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Brian T Hill, MD, PhD
Director, Lymphoid Malignancy Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Ian W Flinn, MD, PhD
Director of Lymphoma Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

RTP
RESEARCH
TO PRACTICE

Meet The Professor Program Participating Faculty

Anthony R Mato, MD, MSCE
Associate Attending
Director, Chronic Lymphocytic Leukemia Program
Memorial Sloan Kettering Cancer Center
New York, New York

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

John M Pagel, MD, PhD
Chief of Hematologic Malignancies
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

Jeff Sharman, MD
Willamette Valley Cancer Institute and Research Center
Medical Director of Hematology Research
US Oncology
Eugene, Oregon

RTP
RESEARCH TO PRACTICE

Meet The Professor Program Participating Faculty

Mitchell R Smith, MD, PhD
Professor of Medicine
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
GW Cancer Center
Washington, DC

Jennifer Woyach, MD
Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Comprehensive Cancer Center
Columbus, Ohio

William G Wierda, MD, PhD
DB Lane Cancer Research
Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

RTP
RESEARCH
TO PRACTICE

Meet The Professor Program Moderator



Project Chair
Neil Love, MD
Research To Practice
Miami, Florida

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program commences and throughout the program.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

ONCOLOGY TODAY

WITH DR NEIL LOVE

Listen on Apple Podcasts

Spotify

Listen on Google Podcasts



Clinical Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

A Meet The Professor Series

Friday, September 11, 2020
12:00 PM – 1:00 PM ET

Faculty

Robert L Coleman, MD

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia

A Meet The Professor Series

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Erik J Rupard, MD
Chief, Section of Hematology-Oncology
McGlinn Cancer Institute
Reading Hospital and Medical Center
West Reading, Pennsylvania

RTP
RESEARCH
TO PRACTICE

Meet The Professor with Dr Rogers

MODULE 1: Cases from the Community – Dr Rupard

- A 39-year-old woman with newly diagnosed CLL
- Questions: Considerations for the up-front treatment of CLL
- A 48-year-old woman with cutaneous CLL
- A 67-year-old man with CLL and del(17p)

MODULE 2: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios

MODULE 3: Key Recent Data Sets

- PFS and rate and duration of MRD negativity with venetoclax/obinutuzumab (CLL14 trial)
- FDA approval of acalabrutinib (ELEVATE-TN trial)
- Ibrutinib/rituximab in older (Alliance A041202 trial) and younger (ECOG-E1912 trial) patients
- CAPTIVATE MRD cohort
- Available data and current clinical role of ibrutinib/obinutuzumab (iLLUMINATE trial)
- Venetoclax/rituximab (MURANO trial)
- Acalabrutinib (ASCEND trial)
- Side effects associated with BTK inhibitors and venetoclax-associated toxicities

RTP
RESEARCH
TO PRACTICE

Case Presentation – Dr Rupard: A 39-year-old woman with newly diagnosed CLL

Dr Eric Rupard

- 2018: Slowly declining Hgb, fatigue. Diagnosed with CLL, with 13q
- Ibrutinib 420 mg daily, with quadrupling of WBC (see image)
  - 6 months later: Slow decline in WBC
  - 6 months later: Slight increase in WBC
  - Improvement in fatigue
- Patient desires to continue treatment with ibrutinib

Questions

- Have you seen patients with very prolonged, ongoing white blood cell/lymphocyte responses to Bruton tyrosine kinase inhibitors?
- At what point do you decide that the BTK inhibitor is not working and move on to another treatment?

Case Presentation Continued: WBC count over time on ibrutinib



Dr Eric Rupard

RTP
RESEARCH
TO PRACTICE

Comments and Questions: Considerations for the up-front treatment of CLL

Dr Eric Rupard

RTP
RESEARCH
TO PRACTICE

Case Presentation – Dr Rupard: A 48-year-old woman with cutaneous CLL

Dr Eric Rupard

- 2013: Diagnosed with CLL, with del 13q → Observation
- 2015: Developed cutaneous disease (see pics)
- Bendamustine/rituximab, with resolution of leukemia cutis in one week (see after pic) → Lost to follow up
- 2018: Fatigue, pain, weight loss LUQ pain and visible spleen (massive)
- Bendamustine monotherapy (traveling the next day) → Lost to follow up
- 7/2020: Mild cutaneous CLL recurrence
- Ibrutinib 420 mg daily

Case Presentation Continued: A 48-year-old woman with cutaneous CLL

Dr Eric Rupard





Case Presentation – Dr Rupard: A 67-year-old man with CLL and del(17p)

Dr Eric Rupard

- 2008: Diagnosed with CLL, CD-38-negative, del(17p) → BR, with CR
- 2015: WBC rising, platelets falling, bothersome LAD
- Rituximab monotherapy (Ibrutinib not feasible financially)
  - Complicated by necrotizing fasciitis, s/p BKA LLE → Recovered
- 2017: Ibrutinib, with remission in about 4 months
- 7/2019: Cellulitis of left leg stump, atrial fibrillation → Ibrutinib discontinued
- 1/2020: b-sxs (NS/fatigue/LOW) plus LAD → Acalabrutinib 100 mg daily
- 7/2020: Admit SOB, pericardial effusion; CT CAP: Bulky disease chest/abd; Biopsy: DLBCL
- Recommended R-CHOP, but due to second tele-opinion: Gem/carbo, with minimal response → Hospice

Questions

- Have you seen this kind of infectious complication shortly after rituximab?
- Do you rechallenge patients who have had atrial fibrillation on ibrutinib and have been cardioverted out of it? Or, do you try to avoid the BTK inhibitors in the future?
- What is the safety of acalabrutinib in somebody who had previously had atrial fibrillation on ibrutinib?

Meet The Professor with Dr Rogers

MODULE 1: Cases from the Community – Dr Rupard

- A 39-year-old woman with newly diagnosed CLL
- Questions: Considerations for the up-front treatment of CLL
- A 48-year-old woman with cutaneous CLL
- A 67-year-old man with CLL and del(17p)

MODULE 2: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios

MODULE 3: Key Recent Data Sets

- PFS and rate and duration of MRD negativity with venetoclax/obinutuzumab (CLL14 trial)
- FDA approval of acalabrutinib (ELEVATE-TN trial)
- Ibrutinib/rituximab in older (Alliance A041202 trial) and younger (ECOG-E1912 trial) patients
- CAPTIVATE MRD cohort
- Available data and current clinical role of ibrutinib/obinutuzumab (iLLUMINATE trial)
- Venetoclax/rituximab (MURANO trial)
- Acalabrutinib (ASCEND trial)
- Side effects associated with BTK inhibitors and venetoclax-associated toxicities

RTP
RESEARCH
TO PRACTICE

What is your usual preferred initial regimen for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who requires treatment?

1. FCR
2. Ibrutinib
3. Ibrutinib + rituximab
4. Ibrutinib + obinutuzumab
5. Acalabrutinib
6. Acalabrutinib + obinutuzumab
7. Venetoclax + obinutuzumab
8. Other

What is your usual preferred initial regimen for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who requires treatment?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Venetoclax + obinutuzumab
 BRIAN T HILL, MD, PHD	Venetoclax + obinutuzumab
 BRAD S KAHL, MD	Venetoclax + obinutuzumab
 ANTHONY R MATO, MD, MSCE	Venetoclax + obinutuzumab
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Acalabrutinib or venetoclax + obinutuzumab
 JEFF SHARMAN, MD	Acalabrutinib
 MITCHELL R SMITH, MD, PHD	Venetoclax + obinutuzumab
 WILLIAM G WIERDA, MD, PHD	Venetoclax + obinutuzumab
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

What is your usual preferred initial regimen for a 75-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who requires treatment?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Acalabrutinib
 BRIAN T HILL, MD, PHD	Venetoclax + obinutuzumab
 BRAD S KAHL, MD	Venetoclax + obinutuzumab
 ANTHONY R MATO, MD, MSCE	Acalabrutinib
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Acalabrutinib or venetoclax + obinutuzumab
 JEFF SHARMAN, MD	Acalabrutinib
 MITCHELL R SMITH, MD, PHD	Ibrutinib
 WILLIAM G WIERDA, MD, PHD	Acalabrutinib
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

What is your usual preferred initial regimen for a 75-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who requires treatment and has bulky disease?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Acalabrutinib
 BRIAN T HILL, MD, PHD	Venetoclax + obinutuzumab
 BRAD S KAHL, MD	Venetoclax + obinutuzumab
 ANTHONY R MATO, MD, MSCE	Acalabrutinib + obinutuzumab
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Acalabrutinib
 JEFF SHARMAN, MD	Acalabrutinib
 MITCHELL R SMITH, MD, PHD	Venetoclax + obinutuzumab
 WILLIAM G WIERDA, MD, PHD	Acalabrutinib
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

What is your usual preferred initial regimen for a 60-year-old patient with CLL with IGHV mutation but no del(17p) or TP53 mutation who requires treatment?

1. FCR
2. Ibrutinib
3. Ibrutinib + rituximab
4. Ibrutinib + obinutuzumab
5. Acalabrutinib
6. Acalabrutinib + obinutuzumab
7. Venetoclax + obinutuzumab
8. Other

What is your usual preferred initial regimen for a 60-year-old patient with CLL with IGHV mutation but no del(17p) or TP53 mutation who requires treatment?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Venetoclax + obinutuzumab
 BRIAN T HILL, MD, PHD	Venetoclax + obinutuzumab or BR
 BRAD S KAHL, MD	Venetoclax + obinutuzumab
 ANTHONY R MATO, MD, MSCE	FCR
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Ibrutinib or FCR
 JEFF SHARMAN, MD	FCR
 MITCHELL R SMITH, MD, PHD	FCR
 WILLIAM G WIERDA, MD, PHD	FCR
 JENNIFER WOYACH, MD	Venetoclax + obinutuzumab

BR = bendamustine/rituximab; FCR = fludarabine/cyclosphosphamide/rituximab (FCR)

What is your usual preferred initial regimen for a 75-year-old patient with CLL with IGHV mutation but no del(17p) or TP53 mutation who requires treatment?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Acalabrutinib
 BRIAN T HILL, MD, PHD	Obinutuzumab
 BRAD S KAHL, MD	Venetoclax + obinutuzumab
 ANTHONY R MATO, MD, MSCE	Acalabrutinib
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Acalabrutinib or venetoclax + obinutuzumab
 JEFF SHARMAN, MD	Venetoclax + obinutuzumab
 MITCHELL R SMITH, MD, PHD	Ibrutinib
 WILLIAM G WIERDA, MD, PHD	Venetoclax + obinutuzumab
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

What is your usual preferred initial regimen for a 60-year-old patient with del(17p) CLL who requires treatment?

 MATTHEW S DAVIDS, MD, MMSC	Ibrutinib
 IAN W FLINN, MD, PHD	Acalabrutinib
 BRIAN T HILL, MD, PHD	Acalabrutinib
 BRAD S KAHL, MD	Acalabrutinib + obinutuzumab
 ANTHONY R MATO, MD, MSCE	Acalabrutinib
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Ibrutnib
 JEFF SHARMAN, MD	Acalabrutinib
 MITCHELL R SMITH, MD, PHD	Venetoclax + obinutuzumab
 WILLIAM G WIERDA, MD, PHD	Acalabrutinib
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

Based on current clinical trial data and your personal experience, how would you compare the global efficacy of acalabrutinib to that of ibrutinib for CLL?

 MATTHEW S DAVIDS, MD, MMSC	About the same
 IAN W FLINN, MD, PHD	About the same
 BRIAN T HILL, MD, PHD	About the same
 BRAD S KAHL, MD	About the same
 ANTHONY R MATO, MD, MSCE	About the same
 JOHN M PAGEL, MD, PHD	About the same
 KERRY A ROGERS, MD	About the same
 JEFF SHARMAN, MD	Not enough data are currently available
 MITCHELL R SMITH, MD, PHD	About the same
 WILLIAM G WIERDA, MD, PHD	About the same
 JENNIFER WOYACH, MD	About the same

RTP RESEARCH TO PRACTICE

Based on current clinical trial data and your personal experience, how would you compare the global efficacy of a single-agent Bruton tyrosine kinase (BTK) inhibitor to that of venetoclax/obinutuzumab for CLL?

 MATTHEW S DAVIDS, MD, MMSC	Not enough data are currently available
 IAN W FLINN, MD, PHD	About the same
 BRIAN T HILL, MD, PHD	A single-agent BTK inhibitor is more efficacious
 BRAD S KAHL, MD	About the same
 ANTHONY R MATO, MD, MSCE	About the same
 JOHN M PAGEL, MD, PHD	Venetoclax/obinutuzumab is more efficacious
 KERRY A ROGERS, MD	Not enough data are currently available
 JEFF SHARMAN, MD	A single-agent BTK inhibitor is more efficacious
 MITCHELL R SMITH, MD, PHD	Not enough data are currently available
 WILLIAM G WIERDA, MD, PHD	I don't know
 JENNIFER WOYACH, MD	Not enough data are currently available

RTP RESEARCH TO PRACTICE

What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has detectable MRD after 1 year of treatment?

1. Continue treatment
2. Discontinue treatment

What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has detectable minimal residual disease (MRD) after 1 year of treatment?

 MATTHEW S DAVIDS, MD, MMSC	Discontinue treatment
 IAN W FLINN, MD, PHD	Discontinue treatment
 BRIAN T HILL, MD, PHD	Discontinue treatment
 BRAD S KAHL, MD	Discontinue treatment
 ANTHONY R MATO, MD, MSCE	Continue treatment
 JOHN M PAGEL, MD, PHD	Continue treatment
 KERRY A ROGERS, MD	Discontinue treatment
 JEFF SHARMAN, MD	Discontinue treatment
 MITCHELL R SMITH, MD, PHD	Discontinue treatment
 WILLIAM G WIERDA, MD, PHD	Continue treatment
 JENNIFER WOYACH, MD	Discontinue treatment

RTP RESEARCH TO PRACTICE

What would be your most likely approach for a patient with newly diagnosed CLL to whom you administer up-front venetoclax/obinutuzumab who has achieved undetectable MRD status after 1 year of treatment?

 MATTHEW S DAVIDS, MD, MMSC	Discontinue treatment
 IAN W FLINN, MD, PHD	Discontinue treatment
 BRIAN T HILL, MD, PHD	Discontinue treatment
 BRAD S KAHL, MD	Discontinue treatment
 ANTHONY R MATO, MD, MSCE	Discontinue treatment
 JOHN M PAGEL, MD, PHD	Discontinue treatment
 KERRY A ROGERS, MD	Discontinue treatment
 JEFF SHARMAN, MD	Discontinue treatment
 MITCHELL R SMITH, MD, PHD	Discontinue treatment
 WILLIAM G WIERDA, MD, PHD	Discontinue treatment
 JENNIFER WOYACH, MD	Discontinue treatment

RTP RESEARCH TO PRACTICE

Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to ibrutinib and then experiences disease progression 3 years later?

1. Acalabrutinib
2. Acalabrutinib + obinutuzumab
3. Venetoclax
4. Venetoclax + rituximab
5. Venetoclax + obinutuzumab
6. Idelalisib
7. Duvelisib
8. Other

Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to ibrutinib and then experiences disease progression 3 years later?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + rituximab
 IAN W FLINN, MD, PHD	Venetoclax + obinutuzumab
 BRIAN T HILL, MD, PHD	Venetoclax + rituximab
 BRAD S KAHL, MD	Venetoclax + rituximab
 ANTHONY R MATO, MD, MSCE	Venetoclax + rituximab
 JOHN M PAGEL, MD, PHD	Venetoclax
 KERRY A ROGERS, MD	Venetoclax + rituximab
 JEFF SHARMAN, MD	Venetoclax + rituximab
 MITCHELL R SMITH, MD, PHD	Venetoclax + obinutuzumab
 WILLIAM G WIERDA, MD, PHD	Venetoclax + rituximab
 JENNIFER WOYACH, MD	Venetoclax + rituximab

RTP RESEARCH TO PRACTICE

Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with no IGHV mutation and no del(17p) or TP53 mutation who responds to venetoclax/obinutuzumab and then experiences disease progression 3 years later?

1. Ibrutinib
2. Ibrutinib + rituximab
3. Ibrutinib + obinutuzumab
4. Acalabrutinib
5. Acalabrutinib + obinutuzumab
6. Idelalisib
7. Duvelisib
8. Other

Which second-line systemic therapy would you recommend for a 60-year-old patient with CLL with unmutated IGHV and no del(17p) or TP53 mutation who responds to venetoclax/obinutuzumab and then experiences disease progression 3 years later?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax + obinutuzumab
 IAN W FLINN, MD, PHD	Acalabrutinib
 BRIAN T HILL, MD, PHD	Acalabrutinib
 BRAD S KAHL, MD	Acalabrutinib
 ANTHONY R MATO, MD, MSCE	Venetoclax + rituximab
 JOHN M PAGEL, MD, PHD	Acalabrutinib
 KERRY A ROGERS, MD	Ibrutinib
 JEFF SHARMAN, MD	Acalabrutinib
 MITCHELL R SMITH, MD, PHD	Ibrutinib
 WILLIAM G WIERDA, MD, PHD	Venetoclax + rituximab
 JENNIFER WOYACH, MD	Ibrutinib

RTP RESEARCH TO PRACTICE

A 60-year-old patient with CLL, an absolute lymphocyte count of 20,000 and several involved lymph nodes that are smaller than 2 centimeters is about to receive venetoclax. What preemptive measures, if any, would you take to address tumor lysis syndrome prior to the initiation of therapy?

 MATTHEW S DAVIDS, MD, MMSC	Encourage oral hydration and allopurinol
 IAN W FLINN, MD, PHD	IV hydration and allopurinol
 BRIAN T HILL, MD, PHD	Encourage oral hydration and allopurinol
 BRAD S KAHL, MD	Encourage oral hydration and allopurinol
 ANTHONY R MATO, MD, MSCE	IV hydration and allopurinol
 JOHN M PAGEL, MD, PHD	Encourage oral hydration and allopurinol
 KERRY A ROGERS, MD	Encourage oral hydration and allopurinol
 JEFF SHARMAN, MD	Give the obinutuzumab first to debulk, then after 1 month can start as outpatient with hydration and allopurinol
 MITCHELL R SMITH, MD, PHD	Encourage oral hydration and allopurinol
 WILLIAM G WIERDA, MD, PHD	Encourage oral hydration and allopurinol
 JENNIFER WOYACH, MD	Encourage oral hydration and allopurinol

RTP RESEARCH TO PRACTICE

A 60-year-old patient with CLL, an absolute lymphocyte count of 80,000 and several involved lymph nodes that are larger than 5 centimeters is about to receive venetoclax. What preemptive measures, if any, would you take to address tumor lysis syndrome prior to the initiation of therapy?

 MATTHEW S DAVIDS, MD, MMSC	Admit to hospital
 IAN W FLINN, MD, PHD	Debulk with obinutuzumab
 BRIAN T HILL, MD, PHD	Admit to hospital
 BRAD S KAHL, MD	Admit to hospital
 ANTHONY R MATO, MD, MSCE	Admit to hospital
 JOHN M PAGEL, MD, PHD	Admit to hospital
 KERRY A ROGERS, MD	Admit to hospital
 JEFF SHARMAN, MD	Obinutuzumab for 1 month to lower patient risk, then outpatient hydration and allopurinol
 MITCHELL R SMITH, MD, PHD	Admit to hospital
 WILLIAM G WIERDA, MD, PHD	Admit to hospital
 JENNIFER WOYACH, MD	IV hydration and allopurinol

RTP RESEARCH TO PRACTICE

For your patients with CLL whom you admit to the hospital to receive venetoclax, for how long do you typically admit them?

 MATTHEW S DAVIDS, MD, MMSC	8 days
 IAN W FLINN, MD, PHD	2 days
 BRIAN T HILL, MD, PHD	2 days (<48 hours)
 BRAD S KAHL, MD	2 days
 ANTHONY R MATO, MD, MSCE	2-3 days
 JOHN M PAGEL, MD, PHD	1 day

 KERRY A ROGERS, MD	2 nights for each dose escalation
 JEFF SHARMAN, MD	2 days
 MITCHELL R SMITH, MD, PHD	1- 2 days
 WILLIAM G WIERDA, MD, PHD	2 days
 JENNIFER WOYACH, MD	2 days or rapid escalation to full dose over 5 days

RTP RESEARCH TO PRACTICE

Based on current clinical trial data and your personal experience, how would you compare the tolerability/toxicity of acalabrutinib to that of ibrutinib for CLL?

 MATTHEW S DAVIDS, MD, MMSC	Acalabrutinib has less toxicity
 IAN W FLINN, MD, PHD	Acalabrutinib has less toxicity
 BRIAN T HILL, MD, PHD	Acalabrutinib has less toxicity
 BRAD S KAHL, MD	Acalabrutinib has less toxicity
 ANTHONY R MATO, MD, MSCE	Acalabrutinib has less toxicity
 JOHN M PAGEL, MD, PHD	Acalabrutinib has less toxicity
 KERRY A ROGERS, MD	Acalabrutinib has less toxicity
 JEFF SHARMAN, MD	Acalabrutinib has less toxicity
 MITCHELL R SMITH, MD, PHD	Acalabrutinib has less toxicity
 WILLIAM G WIERDA, MD, PHD	Acalabrutinib has less toxicity
 JENNIFER WOYACH, MD	Acalabrutinib has less toxicity

RTP RESEARCH TO PRACTICE

Based on current clinical trial data and your personal experience, how would you compare the tolerability/toxicity of a single-agent BTK inhibitor to that of venetoclax/obinutuzumab for CLL?

 MATTHEW S DAVIDS, MD, MMSC	Venetoclax/obinutuzumab has less toxicity
 IAN W FLINN, MD, PHD	Venetoclax/obinutuzumab has less toxicity
 BRIAN T HILL, MD, PHD	Venetoclax/obinutuzumab has less toxicity
 BRAD S KAHL, MD	Venetoclax/obinutuzumab has less toxicity
 ANTHONY R MATO, MD, MSCE	Venetoclax/obinutuzumab has less toxicity
 JOHN M PAGEL, MD, PHD	About the same
 KERRY A ROGERS, MD	Venetoclax/obinutuzumab has less toxicity
 JEFF SHARMAN, MD	Venetoclax/obinutuzumab has less toxicity
 MITCHELL R SMITH, MD, PHD	A single-agent BTK inhibitor has less toxicity
 WILLIAM G WIERDA, MD, PHD	Venetoclax/obinutuzumab has less toxicity
 JENNIFER WOYACH, MD	About the same

RTP RESEARCH TO PRACTICE

Meet The Professor with Dr Rogers

MODULE 1: Cases from the Community – Dr Rupard

- A 39-year-old woman with newly diagnosed CLL
- Questions: Considerations for the up-front treatment of CLL
- A 48-year-old woman with cutaneous CLL
- A 67-year-old man with CLL and del(17p)

MODULE 2: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios

MODULE 3: Key Recent Data Sets

- PFS and rate and duration of MRD negativity with venetoclax/obinutuzumab (CLL14 trial)
- FDA approval of acalabrutinib (ELEVATE-TN trial)
- Ibrutinib/rituximab in older (Alliance A041202 trial) and younger (ECOG-E1912 trial) patients
- CAPTIVATE MRD cohort
- Available data and current clinical role of ibrutinib/obinutuzumab (iLLUMINATE trial)
- Venetoclax/rituximab (MURANO trial)
- Acalabrutinib (ASCEND trial)
- Side effects associated with BTK inhibitors and venetoclax-associated toxicities

RTP RESEARCH TO PRACTICE

blood®

How I Treat

How I manage CLL with venetoclax-based treatments

William G. Wierda[1] and Francesco Paolo Tambaro[2]

[1]Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and [2]Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy

blood® 23 APRIL 2020 | VOLUME 135, NUMBER 17

Strategy for Selecting First-Line CLL Treatment

TP53 status (del(17p)/*TP53* mutation)	Age/ fitness	IGHV MS	First-line treatment (in order of authors' preference)
TP53 intact	Younger/ fit	Mutated	(1) FCR (fixed duration), (2) VEN + OBIN (fixed duration), (3) BTKi ± OBIN (continuous)
		Unmutated	(1) VEN + OBIN (fixed-duration), (2) BTKi ± OBIN (continuous)
	Older/ unfit	Mutated	(1) VEN + OBIN (fixed duration), (2) BTKi ± OBIN (continuous)
		Unmutated	(1) BTKi ± OBIN (continuous), (2) VEN + OBIN (fixed-duration)

TP53 status (del(17p)/*TP53* mutation)	Age/ fitness	IGHV MS	First-line treatment (in order of authors' preference)
TP53 deleted and/ or mutated	All	Either	(1) BTKi ± OBIN (continuous), (2) VEN + OBIN (fixed duration), no CIT

Wierda WG, Tambaro FP. Blood 2020;135(17):1421-27.

RTP RESEARCH TO PRACTICE

Strategy for Selecting Treatment of R/R CLL

Prior treatment			Recommendation for next treatment	Allo-SCT planning
CIT	BCL2i	BTKi		
Yes	No	No	VEN + RIT (fixed duration) or BTKi (continuous)	No
		Yes (intolerant)	Alternative BTKi (continuous) or PI3Ki ± CD20 mAb (continuous)	No
		Yes (refractory)	VEN + RIT	Short-term
	Yes	No	BTKi (continuous)	Yes
		Yes (intolerant)	Alternative BTKi (continuous) or PI3Ki ± CD20 mAb (continuous)	Yes
		Yes (refractory)	Clinical trial CIT if no *TP53* abnormality to debulk	Immediate

Prior treatment			Recommendation for next treatment	Allo-SCT planning
CIT	BCL2i	BTKi		
No	No	Yes (intolerant)	Alternative BTKi (continuous) or PI3Ki ± CD20 mAb (continuous)	No
		Yes (refractory)	VEN + RIT (fixed duration)	Yes
	Yes	No	BTKi (continuous)	No
		Yes (intolerant)	Alternative BTKi (continuous) or PI3Ki ± CD20 mAb (continuous)	No
		Yes (refractory)	Clinical trial CIT if no *TP53* abnormality to debulk	Immediate

Allo-SCT, allogeneic stem cell transplant; BCL2i, BCL2 inhibitor; mAb, monoclonal antibody; PI3Ki, PI3K inhibitor.

Wierda WG, Tambaro FP. Blood 2020;135(17):1421-27.

RTP RESEARCH TO PRACTICE

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects

Saba Tariq [1], Sundus Tariq [2], Maliha Khan [3], Aysha Azhar [4], Mukhtiar Baig [5]

Cureus 2020 Jun 29;12(6):e8908.

The NEW ENGLAND JOURNAL of MEDICINE

N Engl J Med 2020;383:460-73

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*

Treatment of Chronic Lymphocytic Leukemia

Jan A. Burger, M.D., Ph.D.

How to select a treatment for an individual patient?

Menu

- Immunochemotherapy
  - FCR
  - BR
  - Chlorambucil/Obinutuzumab
- Novel Agents
  - Ibrutinib ± obinutuzumab
  - Acalabrutinib ± obinutuzumab
  - Venetoclax + Obinutuzumab

Considerations

- If deletion 17p or p53 mutation
  - Chemo not very effective, better off with novel agents
- If IgHV unmutated
  - Chemo less effective than novel agents
- If IgHV mutated
  - Chemo and novels agents are similarly effective

Courtesy of Brad Kahl, MD

Scenario #1

- 52 yo man with CLL requiring treatment.
  - No p53 mutation or 17p deletion.
  - IgHV unmutated.

- Best options include
  1. Venetoclax plus obinutuzumab
  2. BTKi plus obinutuzumab

- Pro's and Con's to each

Courtesy of Brad Kahl, MD

Scenario #2

- 52 yo man with CLL requiring treatment.
  - No p53 mutation by sequencing
  - No 17p deletion or 11q deletion by FISH.
  - IgHV mutated.

- Best options include
  1. FCR
  2. Venetoclax plus obinutuzumab
  3. BTKi plus obinutuzumab
- Pro's and Con's to each

Courtesy of Brad Kahl, MD

Scenario #3

- 72 yo man with CLL requiring treatment.
  - No p53 mutation.
  - No 17p deletion or 11q deletion.
  - IgHV unmutated.

- Best options include
  1. Venetoclax plus obinutuzumab
  2. BTKi

- Pro's and Con's to each.

Courtesy of Brad Kahl, MD

Scenario #4

- 72 yo man with CLL requiring treatment.
  - No p53 mutation or 17p deletion.
  - IgHV mutated.

- Best options include
  1. Venetoclax plus obinutuzumab
  2. BR
  3. BTKi

- Pro's and Con's to each.

Courtesy of Brad Kahl, MD

Scenario #5

- 72 yo man with CLL requiring treatment.
- 17p deletion by FISH

- BTKi plus obinutuzumab

- This is the one scenario where I favor indefinite therapy over time limited therapy

Courtesy of Brad Kahl, MD

CLL14 Phase III Study Schema



Primary endpoint: Progression-free survival

- Treatment duration in both groups: 12 cycles, 28 days each
- No crossover was allowed
- Daily oral venetoclax regimen:
  - Initiated on day 22 of cycle 1, starting with a 5-week dose ramp-up (1 week each of 20, 50, 100 and 200 mg, then 400 mg daily for 1 week)
  - Thereafter continuing at 400 mg daily until completion of cycle 12

www.clinicaltrials.gov (NCT02242942). Accessed August 2020.
Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.

CLL14: Investigator-Assessed Progression-Free Survival



Endpoint	Ven-obin (n = 216)	Chlor-obin (n = 216)	HR	*p*-value
PFS events	30	77	0.35	<0.001
24-mo PFS	88.2%	64.1%	—	—

Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.

CLL14: Updated 3-Year PFS



Median PFS

Ven-Obi: not reached

Clb-Obi: 35.6 months

3-year PFS rate

Ven-Obi: 81.9%

Clb-Obi: 49.5%

HR 0.31, 95% CI [0.22-0.44]

$p < 0.0001$

Al-Sawaf O et al. EHA 2020;Abstract S155.

CLL14: Investigator-Assessed Progression-Free Survival by Prognostic Subgroup

Category	Subgroup	Total n	Chlorambucil-obinutuzumab n	Chlorambucil-obinutuzumab PFS rate month 24 (%)	Venetoclax-obinutuzumab n	Venetoclax-obinutuzumab PFS rate month 24 (%)	Hazard ratio
All		432	216	64.1	216	88.1	0.34
Cytogenetic subgroups as per hierarchy	del(17p)	31	14	23.1	17	64.7	0.33
	del(11q)	74	38	41.3	36	91.2	0.11
	Trisomy 12	76	40	55.6	36	100.0	NE
	No abnormalities	92	42	82.1	50	87.2	0.93
	del(13q)	120	59	78.3	61	88.1	0.45
TP53 deletion and/or mutation	Present	46	22	32.7	24	73.9	0.31
	Not present	287	139	65.0	148	92.1	0.23
IGHV mutation status	Unmutated	244	123	51.0	121	89.4	0.22
	Mutated	159	83	85.6	76	90.3	0.64



Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.

CLL14: PFS by IGHV Mutation and TP53 Status



Median PFS

Ven-Obi & IGHVmut: not reached

Ven-Obi & IGHVunmut: not reached

Clb-Obi & IGHVmut: 42.9 months

Clb-Obi & IGHVunmut: 26.3 months

Al-Sawaf O et al. EHA 2020;Abstract S155.

RTP RESEARCH TO PRACTICE

CLL14: Minimal Residual Disease 3 Months After Treatment

MRD 3 months after treatment	MRD-negative		MRD responders	
	Veneto/obin (N = 216)	Chloram/obin (N = 216)	Veneto/obin (N = 216)	Chloram/obin (N = 216)
MRD in bone marrow	56.9%	17.1%	33.8%	10.6%
Odds ratio, *p*-value	OR: 6.4, $p < 0.0001$		OR: 4.3, $p < 0.0001$	
MRD in peripheral blood	75.7%	35.2%	42.1%	14.4%
Odds ratio, *p*-value	OR: 5.7, $p < 0.0001$		OR: 4.3, $p < 0.0001$	

Fischer K et al. *N Engl J Med* 2019;380(23):2225-36.

CLL14: Landmark Analysis from End of Therapy PFS by MRD Group



Further landmark analysis of PFS by MRD status showed that undetectable MRD translated into improved PFS regardless of the clinical response status at end of therapy.

Fischer K et al. ASH 2019;Abstract 36.

ELEVATE-TN Phase III Trial Schema



Primary endpoint: Progression-free survival

www.clinicaltrials.gov (NCT02475681). Accessed August 2020.

ELEVATE-TN: PFS (IRC)



Sharman JP et al. *Lancet* 2020;395:1278-91.

ELEVATE-TN: Select Safety Parameters

	Acalabrutinib/obinutuzumab (n = 178)		Acalabrutinib (n = 179)		Obinutuzumab/chlorambucil (n = 169)	
	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3	Grade 1-2	Grade ≥3
Any AE	26%	70%	45%	50%	29%	70%
Serious AE	6%	33%	2%	30%	2%	20%
AE leading to drug discontinuation	11%		9%		14%	
Neutropenia	2%	30%	1%	10%	4%	41%
Grade ≥3 infections						
Infusion-related reactions	11%	2%	0	0	34%	5%

Sharman JP et al. *Lancet* 2020;395:1278-91.

Phase III Alliance A041202 Study Design



Primary endpoint: Progression-free survival (PFS)
Secondary endpoints: OS, ORR, Impact of MRD on PFS and OS, Duration of response, Toxicity and Tolerability

Woyach JA et al. *N Engl J Med* 2018;379(26):2517-28.
Woyach J et al. Alliance Fall Group Meeting, November 5, 2015.

Alliance A041202: Efficacy with Ibrutinib Alone or in Combination with Rituximab Compared to Bendamustine/Rituximab



Woyach JA et al. *N Engl J Med* 2018;379(26):2517-28.

Alliance A041202: Grade 3 to 5 Adverse Events of Special Interest

Adverse event	Bendamustine + rituximab (N = 176)	Ibrutinib (N = 180)	Ibrutinib + rituximab (N = 181)	*p*-value
Hematologic – Any Grade 3-4	**61%**	**41%**	**39%**	**<0.001**
Anemia	12%	12%	6%	0.09
Decreased neutrophil count	40%	15%	21%	<0.001
Decreased platelet count	15%	7%	5%	0.008
Nonhematologic – Any Grade 3-5	**63%**	**74%**	**74%**	**0.04**
Bleeding	0	2%	3%	0.46
Infections	15%	20%	21%	0.62
Febrile neutropenia	7%	2%	1%	<0.001
Atrial fibrillation	3%	9%	6%	0.05
Hypertension	15%	29%	34%	<0.001

Woyach JA et al. *N Engl J Med* 2018;379(26):2517-28.

FDA Approval of Ibrutinib with Rituximab for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Press Release – April 21, 2020

"The Food and Drug Administration expanded the indication of ibrutinib to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Approval was based on the E1912 trial (NCT02048813), a 2:1 randomized, multicenter, open-label, actively controlled trial of ibrutinib with rituximab compared to fludarabine, cyclophosphamide, and rituximab (FCR) in 529 adult patients 70 years or younger with previously untreated CLL or SLL requiring systemic therapy. Patients with 17p deletion were excluded. Ibrutinib was administered at 420 mg daily until disease progression or unacceptable toxicity."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia

Phase III ECOG-ACRIN E1912 Study Design



Primary endpoint: PFS
Secondary endpoints: OS, ORR, Toxicity and Tolerability

ECOG-ACRIN E1912 Physician Fact Sheet, version 01/15/16;
www.clinicaltrials.gov (NCT02048813); Shanafelt TD et al. ASH 2018;Abstract LBA-4.

ECOG-ACRIN E1912 Extended Follow-Up: Up-Front IR Compared to FCR for Younger Patients with CLL



- Grade ≥3 treatment-related AEs were reported in 70% of patients receiving IR and 80% of patients receiving FCR (odds ratio = 0.56; $p = 0.013$).
- Among the 95 patients who discontinued ibrutinib, the most common cause was AE or complication.

Shanafelt TD et al. ASH 2019;Abstract 33.

RTP RESEARCH TO PRACTICE

ECOG-ACRIN E1912 Extended Follow-Up: PFS by IGHV Mutation Status



- On subgroup analysis by IGHV mutation status, IR was superior to FCR for CLL with no IGHV mutation (HR = 0.28; $p < 0.0001$).
- With current follow-up the difference between IR and FCR is not significant for CLL with IGHV mutation (HR = 0.42; $p = 0.086$).

Shanafelt TD et al. ASH 2019;Abstract 33.

CAPTIVATE MRD Cohort: Study Design



uMRD = undetectable minimal residual disease

Results presented for prerandomization phase of the MRD cohort (n = 164) with 12 cycles of ibrutinib + venetoclax prior to MRD-guided randomization

Siddiqi S et al. EHA 2020;Abstract S158.

CAPTIVATE MRD Cohort: 3 Cycles of Ibrutinib Lead-In





Three cycles of ibrutinib lead-in reduces TLS risk and indication for hospitalization

Siddiqi S et al. EHA 2020;Abstract S158.

CAPTIVATE MRD Cohort: Undetectable MRD Rate

	Peripheral blood n = 163	Bone marrow n = 155
Best response of undetectable MRD in evaluable patients (95% CI)	**75%** (68-82)	**72%** (64-79)

- Rates of undetectable MRD in peripheral blood and bone marrow were highly concordant at Cycle 16 (91%)
- In the all-treated population (N = 164), undetectable MRD was achieved in 75% of patients in peripheral blood and in 68% of patients in bone marrow with up to 12 cycles of combination ibrutinib/venetoclax

Siddiqi S et al. EHA 2020;Abstract S158.

CAPTIVATE MRD Cohort: Undetectable MRD in Patients with CR/PR



Best overall response (up to Cycle 16)	CR n = 84	PR n = 75	ORR (CR + PR) n = 159
Undetectable MRD in PB, n (%)	71 (85)	52 (69)	123 (77)
Undetectable MRD in BM, n (%)	67 (80)	44 (59)	111 (70)

At 15 months, 98% of patients were progression free with no deaths

Siddiqi S et al. EHA 2020;Abstract S158.

CAPTIVATE MRD Cohort: Summary of Grade 3 and 4 AEs of Interest

AEs, n (%)	Ibrutinib lead-in (3 cycles) N = 164		Ibrutinib + venetoclax combination (12 cycles) N = 159		Overall (15 cycles) N = 164
	Grade 3	Grade 4	Grade 3	Grade 4	Grade 3-4
Atrial fibrillation	2 (1)	0	1 (1)	0	3 (2)
Major hemorrhage	0	0	1 (1)	0	1 (1)
Infections	4 (2)	0	10 (6)	0	14 (9)
Neutropenia	4 (2)	7 (4)	27 (17)	26 (16)	58 (35)
Febrile neutropenia	1 (1)	0	2 (1)	0	3 (2)
Laboratory TLS	0	0	2 (1)	0	2 (1)

- Low rates of Grade 3 atrial fibrillation, major hemorrhage, infections, febrile neutropenia and laboratory TLS (no Grade 4 event)
- No patients developed clinical TLS
  - Laboratory TLS reported as AE in 3 patients (only 1 met Howard criteria)
- No fatal AEs

Siddiqi S et al. EHA 2020;Abstract S158.

Phase III iLLUMINATE Study Design



Stratification

- ECOG PS (0-1 vs 2)
- Del(17p)/del(11q) (+/+ vs +/- vs -/+ vs -/-)

Primary endpoint: PFS by IRC in ITT

Secondary endpoints: PFS for patients at high risk (positive for del(17p) or TP53 mutation, del(11q), or no IGHV mutation), MRD, ORR, OS, IRRs, safety

Moreno C et al. *Lancet Oncol* 2019;20(1):43-56.

iLLUMINATE: A Phase III Trial of Ibrutinib and Obinutuzumab as First-Line Therapy for CLL



Most common Grade 3 or 4 AEs

- Neutropenia
- Thrombocytopenia

Serious AEs

- Ibrutinib/obinutuzumab: 58%
- Chlorambucil/obinutuzumab: 35%

Moreno C et al. *Lancet Oncol* 2019;20(1):43-56.

RTP RESEARCH TO PRACTICE

Ongoing Phase III EA9161 Trial Schema

Stratifications
Age: <65 yr vs ≥ 65 yr and <70 yr
PS: 0, 1, vs 2
Stage: 0, 1, or 2 vs 3, 4
Del11q22.3 vs others

Randomize

Arm A
Ibrutinib: Cycles 1-19:d1-28 420mg PO daily
Obinutuzumab: C1 **:** D1:100 mg IV, D2:900 mg IV, D8: 1000 mg IV, D15: 1000 mg IV; C2-6: D1 1000 mg IV
Venetoclax: C3 D1-7 20mg PO daily D8-14 50mg PO daily D15-21 100mg PO daily; D22-28 200 mg PO daily; C4-14: D1-28 400mg PO daily

Arm B
Ibrutinib: Cycles 1-19+:d1-28 420mg PO daily
Obinutuzumab: C1 **:** D1:100 mg IV, D2:900 mg IV, D8: 1000 mg IV, D15: 1000 mg IV; C2-6: D1 1000 mg IV

Courtesy of Brad Kahl, MD

Relapsed/Refractory Disease

MURANO Trial: Survival Analyses with Venetoclax/ Rituximab for R/R CLL (48-Month Median Follow-Up)

	VenR (n = 194)	BR (n = 195)	Hazard ratio	*p*-value
Four-year PFS	57.3%	4.6%	0.19	<0.0001
Four-year OS	85.3%	66.8%	0.41	<0.0001





Seymour JF et al. ASH 2019;Abstract 355.

FDA Approval of Acalabrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Press Release – November 21, 2019

"The Food and Drug Administration approved acalabrutinib for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners.

Approval was based on two randomized, actively controlled trials in patients with CLL: ELEVATE-TN (NCT02475681) and ASCEND (NCT02970318). Efficacy in both trials was based on progression-free survival (PFS) as assessed by independent review. The recommended dose is 100 mg orally every 12 hours."

https://www.fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll

RTP RESEARCH TO PRACTICE

ASCEND Phase III Trial Schema



Primary endpoint: Progression-free survival by IRC

Ghia P et al. EHA 2019;Abstract LBA 2606.
www.clinicaltrials.gov (NCT02970318). Accessed August 2020.

ASCEND: Final Analysis of Investigator-Assessed PFS



After a median of 22 months, acalabrutinib prolonged PFS vs investigator's choice of therapy (estimated 18-mo PFS: 82% and 48%, respectively)

Ghia P et al. EHA 2020;Abstract S159.

ASCEND: Adverse Events of Clinical Interest

Adverse event	Acalabrutinib (n = 154)		IdR (n = 118)	
	Any grade	Grade ≥3	Any grade	Grade ≥3
Atrial fibrillation	6%	1%	3%	1%
Hemorrhage	29%	3%	8%	3%
Major hemorrhage	3%	3%	3%	3%
Hypertension	5%	3%	4%	1%
Infections	63%	20%	65%	25%
Second primary cancer, excluding nonmelanoma skin carcinomas	5%	4%	2%	1%
Tumor lysis syndrome	1%	1%	1%	1%

IdR = rituximab/idelalisib

Ghia P et al. EHA 2020;Abstract S159.

Clinical Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer

A Meet The Professor Series

Friday, September 11, 2020
12:00 PM – 1:00 PM ET

Faculty

Robert L Coleman, MD

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 days.

RTP
RESEARCH
TO PRACTICE